a. Select the best compound(s) for clinical development. b. Conduct Phase I, II, and III clinical trials to assess safety, efficacy, and selectivity in humans. c. Obtain regulatory approvals.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
3-MERCAPTO-3-METHYL-BUTYRYL-TYR-PHE-VAL-ASN-CYS-PRO-D-ARG-GLY-NH2
N-(2-amino-6-(4-methoxyphenyl)pyrimidin-4-yl)methanesulfonamide
(2S)-cyclohexyl({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)ethanoic acid
tert-butyl (S)-3-((5-bromo-2-chloropyrimidin-4-yl)amino)piperidine-1-carboxylate
bis(benzonitrile)palladium(II) dichloride
C16H18N4O2
4-[(2-methoxyethoxy)methyl]benzoic acid
1,2,3,4-tetrakis-O-(3,4,5-trihydroxybenzoyl)-alpha-D-glucopyranose
C21H21BrN2O2
5-BROMO-2-[(4-CHLOROBENZYL)OXY]BENZALDEHYDE
Quinoline-5-sulfonyl Chloride
5-[[4-(2-oxo-2-phenylethoxy)phenyl]methyl]-2,4-thiazolidinedione
3-{[(1S)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
N-[4-(6-chloro-2-isopropylamino-pyrimidin-4-ylsulfamoyl)-phenyl]-acetamide
1-cyclopropyl-3-(4-(5-(2,2-difluoropropyl)-6a-methyl-6-oxo-5,6,6a,7,9,10-hexahydro[1,4]oxazino[3,4-h]pteridin-2-yl)phenyl)urea
methyl (1α,3α,4β)-4-[(tert-butoxycarbonyl)amino]-3-hydroxycyclohexanecarboxylate
4-phenoxy-2-phenylquinazoline
1H-Indazole-3-carboxamide, N-(2-methylphenyl)-
6-(2,6-DICHLOROPHENYL)-8-METHYL-2-METHYLSULFONYL-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE
N-phenylsulfonyl-5-hydroxy-6-methoxy-1H-indole
(2S,3S), 2-[4-methoxybenzylsulfanyl], 3-tertiobutyloxycarbonylamino-hexane-dioic acid 1-allyl ester, 6-tertiobutyl ester
trifluoroacetic acid
2H-Cyclopenta[b]furan-2-carbonitrile,5-(acetyloxy)hexahydro-(9CI)
